Skip to main content
Article thumbnail
Location of Repository

Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety

By A.G. Wade, I. Ford, G. Crawford, A. McConnachie, T. Nir, M. Laudon and N. Zisapel


<p>Background: Melatonin is extensively used in the USA in a non-regulated manner for sleep disorders. Prolonged release melatonin (PRM) is licensed in Europe and other countries for the short term treatment of primary insomnia in patients aged 55 years and over. However, a clear definition of the target patient population and well-controlled studies of long-term efficacy and safety are lacking. It is known that melatonin production declines with age. Some young insomnia patients also may have low melatonin levels. The study investigated whether older age or low melatonin excretion is a better predictor of response to PRM, whether the efficacy observed in short-term studies is sustained during continued treatment and the long term safety of such treatment.</p>\ud \ud <p>Methods: Adult outpatients (791, aged 18-80 years) with primary insomnia, were treated with placebo (2 weeks) and then randomized, double-blind to 3 weeks with PRM or placebo nightly. PRM patients continued whereas placebo completers were re-randomized 1:1 to PRM or placebo for 26 weeks with 2 weeks of single-blind placebo run-out. Main outcome measures were sleep latency derived from a sleep diary, Pittsburgh Sleep Quality Index (PSQI), Quality of Life (World Health Organzaton-5) Clinical Global Impression of Improvement (CGI-I) and adverse effects and vital signs recorded at each visit.</p>\ud \ud <p>Results: On the primary efficacy variable, sleep latency, the effects of PRM (3 weeks) in patients with low endogenous melatonin (6-sulphatoxymelatonin [6-SMT] ≤8 μg/night) regardless of age did not differ from the placebo, whereas PRM significantly reduced sleep latency compared to the placebo in elderly patients regardless of melatonin levels (-19.1 versus -1.7 min; P = 0.002). The effects on sleep latency and additional sleep and daytime parameters that improved with PRM were maintained or enhanced over the 6-month period with no signs of tolerance. Most adverse events were mild in severity with no clinically relevant differences between PRM and placebo for any safety outcome.</p>\ud \ud <p>Conclusions: The results demonstrate short- and long-term efficacy and safety of PRM in elderly insomnia patients. Low melatonin production regardless of age is not useful in predicting responses to melatonin therapy in insomnia. The age cut-off for response warrants further investigation.</p&gt

Topics: R1
Publisher: BioMed Central
Year: 2010
OAI identifier:
Provided by: Enlighten

Suggested articles


  1. (1992). AJ: Sleep propensity free-runs with the temperature, melatonin and cortisol rhythms in a totally blind person. Sleep
  2. (2006). Czeisler CA: Sleep-facilitating effect of exogenous melatonin in healthy young men and women is circadian-phase dependent. Sleep
  3. (2009). Degree of pineal calcification (DOC) is associated with polysomnographic sleep measures in primary insomnia patients. Sleep Med
  4. (1991). DL: The effects of exogenous melatonin on the total sleep time and daytime alertness of chronic insomniacs: a preliminary study. Biological Psychiatry
  5. (1996). E: Nocturnal plasma melatonin levels in patients suffering from chronic primary insomnia.
  6. (1976). ECDEU Assessment Manual for Psychopharmacology (rev
  7. (2009). Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia. Sleep
  8. (2003). et al: Practice parameters for the role of actigraphy in the study of sleep and circadian rhythms: an update for 2002. Sleep
  9. (2009). Kriegsfeld LJ: Aging in the circadian system: considerations for health, disease prevention and longevity. Exp Gerontol
  10. (2009). L: The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia. Int Clin Psychopharmacol
  11. (2006). LK: Recommedations for a standard Reseach Assessment of Insomnia.
  12. (2007). Melatonin and the human hippocampus: a time dependent interplay.
  13. (2005). Melatonin as a hypnotic: pro. Sleep Med Rev
  14. (2007). Melatonin excretion levels and polysomnographic sleep parameters in healthy subjects and patients with sleep-related disturbances. Sleep Med
  15. (1997). Melatonin in humans.
  16. (2006). Melatonin reduces night blood pressure in patients with nocturnal hypertension.
  17. (2003). NK: Measuring well-being rather than the absence of distress symptoms: a comparison of the SF-36 Mental Health subscale and the WHO-Five Well-Being Scale. Int J Methods Psychiatr Res
  18. (2004). Nocturnal 6-sulfatoxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapy.
  19. (1997). Nocturnal melatonin onset is phase locked to the primary sleep gate.
  20. (1989). NPV: Circadian rhythms of melatonin and cortisol in aging. Biological Psychiatry
  21. (2000). Practice parameters for the evaluation of chronic insomnia. Sleep
  22. (2003). Practice parameters for using polysomnography to evaluate insomnia: an update. Sleep
  23. (1997). Relationship between napping and melatonin in the blind.
  24. (1997). Reppert SM: Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron
  25. (1992). Ríos CD, Ronda JM: Association of sleep-wake habits in older people with changes in output of circadian pacemaker. Lancet
  26. (1996). Sack RL: Phase shifting the human circadian clock using melatonin. Behav Brain Res
  27. (1994). Sleep disorders and melatonin rhythms in elderly people.
  28. (2004). Sleep-inducing pharmaceuticals: a comparison of melatonin, zaleplon, zopiclone, and temazepam. Aviation Space Environ Med
  29. (1994). Swaab DF: Alterations in circadian rhythmicity of the vasopressin-producing neurons of the human suprachiasmatic nucleus (SCN) with aging. Brain Res
  30. (2007). Swaab DF: Decreased MT1 melatonin receptor expression in the suprachiasmatic nucleus in aging and Alzheimer’s disease. Neurobiol Aging
  31. (2002). Test-retest reliability and validity of the Pittsburgh Sleep Quality Index in primary insomnia. Psychosomatic Res
  32. (1990). The Benzodiazepine Withdrawal Symptom Questionnaire.
  33. (1989). The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Research
  34. (2005). The relationship between melatonin and cortisol rhythms: clinical implications of melatonin therapy. Drug Dev Res
  35. (1999). Urinary 6-sulfatoxymelatonin excretion and aging: new results and a critical review of the literature.
  36. (2005). Vohra S: The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis.
  37. (2003). Wirz-Justice A: Role of melatonin in the regulation of human circadian rhythms and sleep.
  38. (1991). World Psychiatric Association: The Management of Insomnia, Guidelines for Clinical Practice.
  39. (1975). Wurtman RJ: Melatonin excretion of man and rats: effect of time of day, sleep, pinealectomy and food consumption.
  40. (1999). Zaleplon, a novel nonbenzodiazepine hypnotic, effectively treats insomnia in elderly patients without causing rebound effects. Primary Care Companion J Clin Psychiatry
  41. (2007). Zisapel N: Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes. Curr Med Res Opin
  42. (1995). Zisapel N: Improvement of sleep quality in elderly people by controlled-release melatonin. Lancet
  43. (1995). Zisapel N: Melatonin replacement therapy of elderly insomniacs. Sleep
  44. (2007). Zisapel N: Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects.
  45. (2006). Zisapel N: Sleepanticipating effects of melatonin in the human brain. Neuroimage

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.